Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   3:59:53 PM EDT
145.38
+3.18 (+2.24%)
Products, Regulatory

Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints In Helios-A Phase 3 Study

Published: 05/23/2022 11:58 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Presents New 18-month Results From Exploratory Cardiac Endpoints in Helios-a Phase 3 Study of Investigational Vutrisiran.
Alnylam Pharmaceuticals Inc - Reductions in Technetium Uptake Observed in Patients With High Grade Uptake at Baseline.
Alnylam Pharmaceuticals Inc - Improvements in Nt-probnp and Echocardiographic Parameters Seen in Cardiac Subpopulation.
Alnylam - Findings From Helios-a Suggest Treatment With Investigational Vutrisiran May Benefit Patients With Hattr Amyloidosis & Cardiac Involvement.